Status:
NOT_YET_RECRUITING
PillBot™ - Remotely Controlled Capsule Endoscopy
Lead Sponsor:
Endiatx
Conditions:
Gastric Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The PillBot System is an endoscopic capsule imaging system intended for visualization of the stomach. In contrast to currently used passive capsule endoscopy systems, and FDA cleared active magnetic s...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Ability to provide written, informed consent to undergo both capsule endoscopy (un-sedated) and conventional OGD
- Willing and able to complete study follow-up requirements
- Patient has appropriate indications for upper endoscopy including symptoms of, but not limited to upper abdominal pain, acid reflux, heartburn, iron deficiency anemia, weight loss, bloating, belching, nausea, vomiting and atypical chest pain
Exclusion
- All patients who meet any of the following criteria should not be enrolled into the study:
- Coagulopathy with INR \> 1.5, thrombocytopenia with platelet counts \< 50,000
- Active bleeding
- Need for therapeutic procedures during endoscopy
- Lactation
- Dysphagia, or other swallowing disorders
- Known esophageal diverticulum or stricture
- Swallowing disorder
- Known luminal, gastrointestinal strictures
- Patient with Crohn's disease or other potential obstructive conditions, unless there is a recent Computed tomography enterography (CTE) or Magnetic resonance enterography (MRE), MRE or patency capsule performed to exclude an obstructive lesion that may retain the capsule
- History of esophageal, gastric surgery or intestinal surgery
- Esophageal or GI motility disorder
- Known or suspected gastrointestinal obstruction, significant intestinal strictures, or fistulas based on the clinical picture or pre-procedure testing and profile.
- Current participation in another investigational drug or device treatment study
- Pregnant or wishes to become pregnant during the study follow-up period
- Patient with implanted medical device that would be potentially affected radiofrequency emissions (e.g., pacemakers, implanted cardiac defibrillators)
- Severe psychiatric, neurological, cardio-vascular, or renal disorders
- History of allergy or intolerance to materials used to make the PillBot
Key Trial Info
Start Date :
May 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06212206
Start Date
May 1 2024
End Date
December 1 2024
Last Update
January 18 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.